Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy [0.03%]
有利风险前列腺癌患者接受质子治疗的长期临床结果
Alicia Bao,Andrew R Barsky,Russell Maxwell et al.
Alicia Bao et al.
Purpose: Long-term data regarding the disease control outcomes of proton beam therapy (PBT) for patients with favorable risk intact prostate cancer (PC) are limited. Herein, we report our institution's long-term disease c...
Dosimetric Results for Adjuvant Proton Radiation Therapy of HPV-Associated Oropharynx Cancer [0.03%]
人乳头瘤病毒相关型口咽癌术后辅助质子放疗剂量学结果分析
Christopher M Wright,Jonathan Baron,Daniel Y Lee et al.
Christopher M Wright et al.
Purpose: One significant advantage of proton therapy is its ability to improve normal tissue sparing and toxicity mitigation, which is relevant in the treatment of oropharyngeal squamous cell carcinoma (OPSCC). Here, we r...
Nuclear Fragmentation Imaging for Carbon-Ion Radiation Therapy Monitoring: an In Silico Study [0.03%]
碳离子放疗监测的核碎片成像：基于计算机模拟的研究
Anissa Bey,Jiasen Ma,Keith M Furutani et al.
Anissa Bey et al.
Purpose: This article presents an in vivo imaging technique based on nuclear fragmentation of carbon ions in irradiated tissues for potential real-time monitoring of carbon-ion radiation therapy (CIRT) treatment delivery ...
Demonstration of the FLASH Effect Within the Spread-out Bragg Peak After Abdominal Irradiation of Mice [0.03%]
小鼠腹部照射后布拉格峰散射区域中FLASH效应的展示
Tucker Evans,James Cooley,Miles Wagner et al.
Tucker Evans et al.
Purpose: The effects of FLASH-level dose rates delivered at the spread-out Bragg peak (SOBP) on normal tissue damage in mice were investigated. Materials ...
Proton Radiotherapy for Patients With Oligometastatic Breast Cancer Involving the Sternum [0.03%]
前列腺中度转移性乳腺癌患者的放射治疗
Andrew Johnson,Nicolas Depauw,Stephen Zieminski et al.
Andrew Johnson et al.
Introduction: A subset of metastatic breast cancer patients present with oligometastatic disease involving the sternum. Given the proximity to traditional target structures, a proton radiation field can be expanded to inc...
Radiation Necrosis with Proton Therapy in a Patient with Aarskog-Scott Syndrome and Medulloblastoma [0.03%]
一名患有Aarskog-Scott综合征和髓母细胞瘤患者接受质子治疗后出现放射性坏死
Vidya Puthenpura,Nicholas J DeNunzio,Xue Zeng et al.
Vidya Puthenpura et al.
Purpose: Medulloblastoma is known to be associated with multiple cancer-predisposition syndromes. In this article, we explore a possible association among a patient's Aarskog-Scott syndrome, development of medulloblastoma...
Evaluating Disparities in Proton Radiation Therapy Use in AHOD1331, a Contemporary Children's Oncology Group Trial for Advanced-Stage Hodgkin Lymphoma [0.03%]
评估先进霍奇金淋巴瘤儿童肿瘤学组当代研究AHOD1331中质子放射治疗使用的差异性
Raymond B Mailhot Vega,Sharon M Castellino,Qinglin Pei et al.
Raymond B Mailhot Vega et al.
The Advantage of Proton Therapy in Hypothalamic-Pituitary Axis and Hippocampus Avoidance for Children with Medulloblastoma [0.03%]
儿童髓母细胞瘤全脑全脊髓照射后中轴系统和海马 proton boost 辐射治疗优势的剂量学研究
Saif Aljabab,Shushan Rana,Shadonna Maes et al.
Saif Aljabab et al.
Purpose: Craniospinal irradiation (CSI) improves clinical outcomes at the cost of long-term neuroendocrine and cognitive sequelae. The purpose of this pilot study was to determine whether hypothalamic-pituitary axis (HPA)...
Insurance Approval for Definitive Proton Therapy for Prostate Cancer [0.03%]
前列腺癌 definitive proton therapy 的保险审批手续
William M Mendenhall,Eric D Brooks,Stephanie Smith et al.
William M Mendenhall et al.
Purpose: To determine factors that influence insurance approval for definitive proton therapy (PT) for prostate cancer. Materials and methods: ...
Measuring Radiation Toxicity Using Circulating Cell-Free DNA in Prostate Cancer Patients [0.03%]
利用循环细胞-freeDNA检测前列腺癌患者的放射毒性
Natalie A Lockney,Randal H Henderson,Steven G Swarts et al.
Natalie A Lockney et al.
Background: After radiation therapy (RT), circulating plasma cell-free DNA (cfDNA) released in response to RT damage to tissue can be measured within hours. We examined for a correlation between cfDNA measured during the ...